| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Immuron Limited | Travelan (IMM-124E) | Gut Health During Travel | Phase 2 | Ongoing | Oral | Gastroenterology |
| Immuron Limited | IMM-529 | C. difficile infection | Phase 2 | IND Clearance | Oral | Antibiotic |
| Immuron Limited | Travelan - (CHIM) | Enterotoxigenic Escherichia coli (ETEC) | Phase 2 | Data Released | Oral | Gastroenterology |
| Immuron Limited | Campylobacter ETEC Therapeutic | Campylobacteriosis | Phase 2 | Oral | N/A | |
| Immuron Limited | Campylobacter ETEC Therapeutic | Campylobacter and enterotoxigenic E.coli (ETEC) infections | Phase 2 | Oral | Antibiotic | |
| Immutep Limited | Eftilagimod alpha and KEYTRUDA (pembrolizumab) - (TACTI-002/KEYNOTE-798) | Non-small cell lung cancer; Head and neck cancer | Phase 2 | Ongoing | Intravenous | Oncology |
| Immutep Limited | Eftilagimod alpha - (EAT COVID) | COVID-19 | Phase 2 | Subcutaneous | COVID-19 | |
| Immutep Limited | GSK2831781 | Ulcerative Colitis | Phase 2 | Trial Discontinued | Intravenous | Gastroenterology |